COVELEC: Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients

Sponsor

Elsan (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT04414059

Collaborator

(none)

200

Enrollment

Locations

Anticipated Duration (Months)

100

Patients Per Site

5.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The inflammation is central in COVID-19 infections. Our aim is to evaluate the clinical value of measuring inflammation by using serum protein electrophoresis (SPE). SPE evaluation of inflammation should be able to predict outcome, follow up evolution or treatment efficacy in patients with coronavirus infection and thus anticipate their evolution to severe viral infection and allow an optimal clinical management. SPE inflammation diagnostics will be benchmarked with other diagnostics of inflammation, currently used more routinely.

Condition or Disease	Intervention/Treatment	Phase
SARS-CoV 2 Hospitalisation-Associated Infection

Detailed Description

In late December 2019, an outbreak of an emerging respiratory disease (COVID-19) caused by a novel coronavirus named SARS-CoV-2 began in Wuhan City, Hubei Province, China and quickly spread in a substantial number of countries. The epidemic was declared a pandemic by the Word Health Organization (WHO) on 12 March 2020. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption.

Both clinical and epidemiological features of patients with COVID-19 have recently been reported, demonstrating that the SARS-CoV-2 infection can be asymptomatic in some cases or symptomatic in others. Symptomatology usually begins as mild with fever, fatigue, dry cough, and occasional dyspnea. In a minority of patients, a sudden onset of severe symptoms may develop 5-8 days into the illness including shortness of breath, pneumonitis, acute respiratory distress syndrome (ARDS) and multi organ dysfunction leading to intensive care unit (ICU) admission and high mortality. In some cases, accumulating evidence suggests that severe COVID-19 symptoms could be due to a cytokine storm syndrome. As of May 3rd 2020, the virus had infected 3,349,786 patients worldwide with more than 238,600 deaths, more often among older patients with underlying health conditions.

With caseloads overwhelming hospitals and resources stretched thin in this surging pandemic (high demand for oxygen, prolonged ventilation and even extracorporeal membrane oxygenation (ECMO), particularly for patients with acute ARDS), there is an urgent need to enhance clinical skills in order to predict from the many mild cases those few that will progress to critical illness allowing a more efficient resource allocation and clinical management.

Several studies on patient blood have described features that were most predictive of ARDS. These studies showed that severe cases, compared to mild cases, had : 1) older age; 2) abnormalities in chest scanning (CT) such as multiple patch-like shadows and ground glass opacity; 3) organ and coagulation dysfunction with a higher levels of alanine aminotransferase (ALT), lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer; 4) as well as markedly higher levels of immunological characteristics such as IL-2R, IL-6, IL-10, and TNF- α ; 5) and an absolute T lymphocytes (CD4+ and CD8+ T cells) number markedly lower in nearly all severe cases. These observations suggest that severity and mortality might be due to virally driven systemic hyperinflammation secondary to failure of the immune response to control infection (as shown for other viruses).

With this study we want to caracterize the predictive performance of the serum inflammation profiles by protein electrophoresis, associated with clinical, radiological and biological risk factors for worsening. This study is a prospective, observational study conducted on patients hospitalized for an infection with the SARS-CoV-2 virus.

Study Design

Study Type:

Observational

Actual Enrollment :

200 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Complications Risk Factors in Patients Hospitalized for COVID-19 Infection: Role of Proteins Electrophoresis

Actual Study Start Date :

Mar 10, 2021

Actual Primary Completion Date :

May 10, 2022

Anticipated Study Completion Date :

Sep 10, 2022

Outcome Measures

Primary Outcome Measures

Complications onset [Up to 3 weeks]
hospitalisation in Intensive Care Unit OR Oxygen needs > 6 L/min OR death whatever the cause

Secondary Outcome Measures

Risk value associated with each risk factor as identified at the end of the main study analysis [Up to 3 weeks]
Risk quantification
Predictive performance and risk associated with each individual protein fraction [Up to 3 weeks]
Correlation between complications onset (as defined by hospitalisation in Intensive Care Unit OR Oxygen needs > 6 L/min OR death whatever the cause) and individual protein fraction value
Intra-patient kinetics evolution of the electrophoresis curves [Up to 3 weeks]
Evolution over time of the serum quantity of each individual protein fraction (6 fractions studied)
Intra-patient kinetics evolution of biological risk factors [Up to 3 weeks]
Evolution over time of the serum quantity of each biological risk factor (as defined for the study)
Inter-expert reproducibility analysis of electrophoretic inflammatory profiles centrally reviewed [After study completion, estimated 10 months after first patient enrolled]
Central review of each serum protein electrophoresis curve
Contribution of urinary electrophoresis inflammation profiles in the interpretation of serum electrophoresis curves [Up to 3 weeks]
Urine samples at admission, every 4 days and at complications onset
Exploratory biological objective: Definition of a more detailed electrophoretic inflammatory profile [After study completion, estimated 10 months after first patient enrolled]
Biobank with serum samples for the implementation, at the end of the study, of a high-resolution capillary electrophoresis technique enabling each serum protein to be viewed individually

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male of female aged 18 or over
Patients with at least one of the following diagnostic criteria, allowing to suspect an infection by the virus SARS-CoV- 2 :
Clinical picture with fever, and/or exertional dyspnea, and/or PO2 < 80mmHg
And/or chest scanner very suggestive or compatible with a COVID-19 infection
And/or a RT-PCR positive result already known
Hospitalized patient in a COVID-19 medical unit, based on one or several diagnostic elements described
Possibility to collect blood and urine samples as described in protocol
Patients informed of the study, having understood it, and who didn't oppose to their participation

Exclusion Criteria:

Clinical condition justifying immediate hospitalization in the intensive care unit
During the initial patient management, an immediate need of oxygen requiring intubation and/or oxygen supply greater than 6 liters / minute
Patients under legal protection
Pregnant or breastfeeding women

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Clinique de l'Estrée	Stains		France
2	Clinique Vauban	Valenciennes		France

Sponsors and Collaborators

Elsan

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:

Elsan

ClinicalTrials.gov Identifier:

NCT04414059

Other Study ID Numbers:

COVELEC
2020-A01376-33

First Posted:

Jun 4, 2020

Last Update Posted:

Jul 25, 2022

Last Verified:

Jul 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Elsan

COVID-19

Additional relevant MeSH terms:

Infections

COVID-19

Study Results

No Results Posted as of Jul 25, 2022